Cangrelor

Indication

Reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti‑platelet therapy

NICE TA 351 - Cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti‑platelet therapy (terminated appraisal)

Black

Brand:

Nice TA:

351

Commissioning responsibility:

CCG

PbR excluded:

No

BNF chapter:

Cardiovascular system

Background

Recommendation

LSCMMG Recommendation:

Black

Reason for decision:

Not recommended for prescribing on the NHS in Lancashire & South Cumbria

Supporting documents:

Decisions of Lancashire local decision making groups

BwD	BP	CSR	EL	FW	GP	MB	WL
Black	Black	Black	Black	Black	Black	Black	Black

What do the colours mean?

Last Updated: 01 - Sep - 2015